GLP-1 products have the potential to narrow health disparities by addressing a key driver of chronic disease
Nausea: 50-66% Diarrhea: 49% Vomiting: 41% Dyspepsia: Elevated risk Discontinuation due to side effects: 15.9-20% The higher side effect rates for Survodutide require context
It changes as you lose weight, and those changes affect which injection site works best at different stages of your journey
You know, the multi-billion-dollar industry that hands out pills like candy, often with way more risk and way less shame attached
saying they currently take the medications
Study Findings The cohorts were analyzed to determine the relationship between the time elapsed from their last semaglutide dose and complications from delayed emergence from anesthesia, aspiration event, aspiration pneumonitis, and conversion to intubation